Company Overview
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.34.
Generates positive free cash flow, funding growth and shareholder returns internally.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +418.52% |
| 6 Months: | +32.88% |
| 3 Months: | +201.54% |
| 1 Month: | +60.72% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)69.16 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FTH Faeth Therapeutics, Inc. PHARMA | 39.20 | -0.64 | $1.01B | 0.00% | -119.50% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -4.10M | -4.91M | -5.36M | -7.97M | -9.78M | -10.32M | -12.49M | -10.71M | -13.94M | -11.01M | -10.18M | -7.74M | -8.73M | -7.79M | -7.82M | -7.27M | -5.21M | -4.85M | -170.63M | -18.39M |
| Net Income | -4.69M | -4.91M | -5.37M | -7.97M | -9.77M | -9.69M | -12.40M | -10.54M | -13.42M | -10.18M | -9.39M | -7.12M | -7.99M | -7.14M | -7.25M | -6.86M | -4.94M | -4.57M | -170.24M | -16.01M |
| Diluted EPS | - | - | - | - | - | -0.32 | -0.40 | -0.34 | -0.44 | -0.33 | -0.31 | -0.28 | -0.32 | -5.69 | -5.77 | -5.45 | -3.91 | -3.62 | -131.45 | -2.84 |
| R&D Expense | 2.19M | - | - | 3.37M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -19.45M | -37.48M | -50.19M | -37.06M | -32.61M | -22.29M |
| Net Income | -20.10M | -36.79M | -48.59M | -34.10M | -30.16M | -21.09M |
| Diluted EPS | - | -1.33 | -1.58 | -1.22 | -24.01 | -16.72 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 21.43M | - | 118.38M | 74.37M | 45.36M | 22.90M |
| Current Assets | - | - | - | 108.59M | 67.25M | 41.93M | 21.51M |
| Cash & Equivalents | - | 16.60M | - | 17.80M | 13.01M | 9.99M | 8.67M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 5.54M | - | 14.97M | 9.48M | 6.97M | 4.31M |
| Current Liabilities | - | 4.83M | - | 9.07M | 5.64M | 5.45M | 4.25M |
| Long Term Debt | - | 567.00K | - | - | - | - | - |
| Total Debt | - | - | - | 8.03M | 6.21M | 3.85M | 1.51M |
| Total Equity | -68.66M | -56.44M | - | 103.41M | 64.89M | 38.39M | 18.59M |
| Shares Outstanding | - | - | - | 1.54M | 1.25M | 1.26M | 1.26M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.70M | -30.26M | -39.03M | -32.02M | -24.67M | -20.45M |
| Investing Cash Flow | -1.40M | -143.12M | 49.95M | 38.41M | 22.44M | 19.77M |
| Financing Cash Flow | 35.45M | 163.94M | -287.00K | -11.17M | -787.00K | -645.00K |
| Capital Expenditure | -1.21M | -2.03M | -321.00K | -180.00K | -146.00K | -16.00K |
| Free Cash Flow | -18.91M | -32.28M | -39.35M | -32.20M | -24.82M | -20.47M |
| Share Buybacks | - | - | - | 10.38M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 35.6% | - | -47.0% | -52.5% | -78.6% | -113.4% |
| ROCE % | -117.2% | - | -45.9% | -53.9% | -81.7% | -119.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Montanova Capital LLC | 7.82% | 2.02M | $69.69M |
| 2 | Avoro Capital Advisors LLC | 5.59% | 1.44M | $49.82M |
| 3 | Baker Bros. Advisors, LP | 4.98% | 1.29M | $44.38M |
| 4 | Balyasny Asset Management LP | 4.03% | 1.04M | $35.96M |
| 5 | Cormorant Asset Management, LP | 3.98% | 1.03M | $35.47M |
| 6 | RA Capital Management, L.P. | 2.79% | 722.02K | $24.91M |
| 7 | Vivo Capital, LLC | 2.79% | 722.02K | $24.91M |
| 8 | Fairmount Funds Management LLC | 2.79% | 722.02K | $24.91M |
| 9 | Logos Global Management LP | 2.79% | 722.02K | $24.91M |
| 10 | Caligan Partners, LP | 2.44% | 629.47K | $21.72M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FTH
About 80% of endometrial tumors have a pathway alteration. Faeth will discuss PIKTOR. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNSXpJRmJRMkJXNERJRlhSNHRoSEV0TjUzdWl0YlZJMGpNNGowYjhtbjBZdmdvbmxfU1lNbHNNajdQcHZoN1cwUlZBX21KX0JTTnoxZkdZeUFJYlZ3Y0hJcGxrSXctOGlVbXUtZWUwdE9rZC1wZ1Robng1cEFqQ1hjbTVQa1FxdkJGeXBWS0…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiT0FVX3lxTFBQdDMzR3BSYlVDTVp4STBMZm91NGdxbUhETi1IYVI3OE1jSk4tTF83MTF5V1kxeFJvWWJQazEzT1pJVWZGUmlpSFlVSm9zQ3M?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <font…
$FTH stock is up 15% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNRTFXQVRiWmpSZzRNNUs0UnJCaGtFNWdKZGR0a0tDckpDLXBhWGlqY1dhMm1ZTV9sVjVGZUMtd21FdEFnLTNVRGNGSlN1QnlPUVNWNFFlak13ZTRCMWNabEtOeTE2MTQwSHBXOTh2Vi1xVjFWS2U1WE1HclZQSTZ5ZnNrMnlRbUwyd2Z6TF…
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQWUVMZ3ZXMV8tQXppa0hDS2VvbWgyeUxnY0l4dVdLV29wLWdoMWJTQVBXVHJuQWgtRTRIcjBnWC1hUVVtMFJTY0FqZm1CbWdWQmdBUmYyNFFQZUxSd2V3YTAzcjVUTDZqNU0yeXhNTTBKRHFCYXBZdkY2Y1lIbFZ2LWFBcHRLMUJ1MUNsR1…
FT stock picking game results: the unexpected triumph of fundamentals - Financial Times
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxPWm93czJmN3I4Y19sQW9FdW9FM0I3UjJ6eHlGai1iNVpJRmxwMDFCWkhJUE1JZ2lYMVRSUlR2S0YwNUxSbFZyLVNnSjlxbm51cl9sTXU4TkZkZHp3RmhKWVhPZlFSaEVyTjk3YXdfX21BblRsT2tTc0xKRFVZSFNBT3VmeGk?oc=5" targ…
Bullish Faeth Therapeutics Insiders Rewarded As Their Investment Rises To US$1.94m - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxNd3dvc0F1dzhDUkpFWXhCZ3pRaU92a1VKWEpsOERVczlDcGtrUmI4cW9NTDg2bGdkcEJ0ZEVqbU9UX0xpZjdtX1pDTlkyVjFFcGZCRFVGTHVibDFNYjdvbV9wMEFSNUItZ2NLOUlCVnZmUzNTWTVQZkNsMk5JdzlMUkYxZHFIZnV4TnhuYU…
FTH — Frequently Asked Questions
What is the current share price of Faeth Therapeutics, Inc. (FTH)?
As of 2026-09-19 21:16 PDT, Faeth Therapeutics, Inc. (FTH) trades at $39.20 on NasdaqCM. Its 52-week range is $7.50 to $40.05.
What is the market capitalisation of FTH?
Faeth Therapeutics, Inc. (FTH) has a market capitalisation of $1.01B on NasdaqCM.
What is the P/E ratio of FTH?
FTH trades at a trailing price-to-earnings (P/E) ratio of -0.64. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.15.
Is FTH a good stock to buy?
This page provides a data-driven analysis of Faeth Therapeutics, Inc. (FTH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.